These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 2113797)

  • 21. The pharmacokinetics and therapeutic efficacy of fleroxacin and pefloxacin in a rat abscess model.
    Leibovitz E; Keren G; Shabtai M; Barzilai A; Rubinstein E
    J Antimicrob Chemother; 1989 Sep; 24(3):375-85. PubMed ID: 2509411
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Renal handling of fleroxacin in rabbits, dogs, and humans.
    Shiba K; Saito A; Shimada J; Hori S; Kaji M; Miyahara T; Kusajima H; Kaneko S; Saito S; Ooie T
    Antimicrob Agents Chemother; 1990 Jan; 34(1):58-64. PubMed ID: 2109576
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Single-dose pharmacokinetics of oral fleroxacin in bacteremic patients.
    Schrenzel J; Cerruti F; Herrmann M; Leemann T; Weidekamm E; Portmann R; Hirschel B; Lew DP
    Antimicrob Agents Chemother; 1994 Jun; 38(6):1219-24. PubMed ID: 8092817
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bioavailability of ciprofloxacin and fleroxacin: results of a preliminary investigation in healthy adult Nigerian male volunteers.
    Chukwuani CM; Coker HA; Oduola AM; Sowunmi A; Ifudu ND
    Biol Pharm Bull; 2000 Aug; 23(8):968-72. PubMed ID: 10963305
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics and metabolism of intravenous and oral fleroxacin in subjects with normal and impaired renal function and in patients on continuous ambulatory peritoneal dialysis.
    Stuck AE; Frey FJ; Heizmann P; Brandt R; Weidekamm E
    Antimicrob Agents Chemother; 1989 Mar; 33(3):373-81. PubMed ID: 2499248
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Single-dose pharmacokinetic study of ciprofloxacin and fleroxacin in healthy adult Nigerian volunteers.
    Chukwuani CM; Coker HA; Oduola AM; Ifudu ND; Sowunmi A
    Chemotherapy; 1998; 44(6):369-76. PubMed ID: 9755295
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Altered disposition of fleroxacin in patients with cystic fibrosis.
    Mimeault J; Vallée F; Seelmann R; Sörgel F; Ruel M; LeBel M
    Clin Pharmacol Ther; 1990 May; 47(5):618-28. PubMed ID: 2111750
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of fleroxacin after multiple oral dosing in patients receiving regular hemodialysis.
    Uehlinger DE; Schaedeli F; Kinzig M; Sörgel F; Frey FJ
    Antimicrob Agents Chemother; 1996 Aug; 40(8):1903-9. PubMed ID: 8843301
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Penetration of fleroxacin into breast milk and pharmacokinetics in lactating women.
    Dan M; Weidekamm E; Sagiv R; Portmann R; Zakut H
    Antimicrob Agents Chemother; 1993 Feb; 37(2):293-6. PubMed ID: 8452360
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of sex on the pharmacokinetic interaction of fleroxacin and ciprofloxacin with caffeine.
    Kim MK; Nightingale C; Nicolau D
    Clin Pharmacokinet; 2003; 42(11):985-96. PubMed ID: 12908854
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The pharmacokinetics of oral fleroxacin and ciprofloxacin in plasma and sputum during acute and chronic dosing.
    Begg EJ; Robson RA; Saunders DA; Graham GG; Buttimore RC; Neill AM; Town GI
    Br J Clin Pharmacol; 2000 Jan; 49(1):32-8. PubMed ID: 10606835
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety of fleroxacin coadministered with theophylline to young and elderly volunteers.
    Parent M; St-Laurent M; LeBel M
    Antimicrob Agents Chemother; 1990 Jun; 34(6):1249-53. PubMed ID: 2118328
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Steady-state pharmacokinetics of ciprofloxacin in plasma from patients with nosocomial pneumonia: penetration of the bronchial mucosa.
    Fabre D; Bressolle F; Gomeni R; Arich C; Lemesle F; Beziau H; Galtier M
    Antimicrob Agents Chemother; 1991 Dec; 35(12):2521-5. PubMed ID: 1810184
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quinolone pharmacokinetics and metabolism.
    Lode H; Höffken G; Boeckk M; Deppermann N; Borner K; Koeppe P
    J Antimicrob Chemother; 1990 Oct; 26 Suppl B():41-9. PubMed ID: 2124212
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Penetration of fleroxacin into maxillary sinus mucosa and palatine tonsil.
    Baba S; Mori Y; Maruo T
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():195-7. PubMed ID: 3144538
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics of Ro 23-6240 (AM 833), a new trifluorinated quinolone.
    Weidekamm E; Stöckel K; Dell D
    Chemioterapia; 1987 Jun; 6(2 Suppl):307-8. PubMed ID: 3151346
    [No Abstract]   [Full Text] [Related]  

  • 37. Fleroxacin clinical pharmacokinetics.
    Stuck AE; Kim DK; Frey FJ
    Clin Pharmacokinet; 1992 Feb; 22(2):116-31. PubMed ID: 1551289
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bactericidal kinetics of various dosages of fleroxacin simulated in bacterial cultures.
    Bauernfeind A; Eberlein E; Hörl G
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():81-9. PubMed ID: 3144553
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics of Ro 23-9424, a dual-action cephalosporin, in animals.
    Christenson JG; Chan KK; Cleeland R; Dix-Holzknecht B; Farrish HH; Patel IH; Specian A
    Antimicrob Agents Chemother; 1990 Oct; 34(10):1895-900. PubMed ID: 2127171
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis.
    Montgomery MJ; Beringer PM; Aminimanizani A; Louie SG; Shapiro BJ; Jelliffe R; Gill MA
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3468-73. PubMed ID: 11709326
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.